<DOC>
	<DOCNO>NCT01196195</DOCNO>
	<brief_summary>The trial evaluate pharmacokinetics , safety , efficacy acceptability twice- once-daily dosing lopinavir/ritonavir tablet ( Kaletra ) dose weight HIV-1 infected child currently take lopinavir/ritonavir part combination antiretroviral therapy currently achieve virological suppression ( &lt; 50 copies/ml ) . Specifically : - To confirm weight-based dose recommendation evaluate pharmacokinetics twice-daily lopinavir/ritonavir half strength formulation tablet dose body weight compare historical adult paediatric data pharmacokinetics lopinavir/ritonavir soft gel capsule oral solution respectively ( 1 , 2 ) . - To compare pharmacokinetics twice-daily lopinavir/ritonavir tablet once-daily dose child . - To evaluate whether once-daily dose lopinavir/ritonavir comparable twice-daily dosing term virological suppression 48 week . Adherence acceptability also compare .</brief_summary>
	<brief_title>KONCERT A Kaletra ONCE Daily Randomised Trial Pharmacokinetics , Safety Efficacy Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed Weight Part Combination Antiretroviral Therapy Human Immunodeficiency Virus-1 ( HIV-1 ) Infected Children ( PENTA 18 )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>age &lt; 18 year ( 18th birthday ) confirm HIV1 infection weight â‰¥15 kg able swallow tablet stable ( i.e . CD4 decline ) combination antiretroviral regimen include lopinavir/ritonavir least 24 week take lopinavir/ritonavir dose twicedaily willing screen visit change tablet formulation ( currently take tablet ) change lopinavir/ritonavir dose follow recommend FDA dose plan base body weight band necessary ( see 7.2.2 ) ; participate PK study* , willing screen visit change lopinavir/ritonavir half strength formulation tablet ( 100/25mg ) , dose twicedaily change lopinavir/ritonavir dose follow recommend FDA dose plan base body weight band necessary ( see 7.2.1 ) viral suppression ( HIV1 RNA &lt; 50 copies/ml ) least prior 24 week ( minimum 2 measurement ) . child caregiver willing participate PK study among minimum first 16 child enrol body weight band trial , include second PK assessment randomise switch oncedaily lopinavir/ritonavir . parents/carers child , applicable , give inform write consent child antiretroviral regimen include nonnucleoside reverse transcriptase inhibitor ( NNRTI ) , fosamprenavir nelfinavir child previously fail virologically protease inhibitor ( PI ) contain regimen ( virological failure define two successive HIV1 RNA result &gt; 1000 copies/ml ( confirm ) 24 week start highly active antiretroviral therapy ( HAART ) , i.e change toxicity count failure ) acute illness abnormal renal liver function ( grade 3 ) receive concomitant therapy except prophylaxis ; Some treatment may allow , must first discuss trial medical expert pregnancy risk pregnancy female child bear potential</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>antiretroviral therapy</keyword>
	<keyword>child</keyword>
	<keyword>HIV-1</keyword>
</DOC>